“gauchers-disease” Archives

Entry Author Date Location
Cydan, NEA’s Orphan Drug Experiment, Pays Off in $200M Vtesse Deal 04/03/17 Boston
It Takes Guts: Blue Turtle Bio on Treating Gaucher with Microbes 02/29/16 Detroit Ann Arbor
Roundup: NextEnergy, Start Garden, LLamasoft, Atterocor, U-M, More 11/20/14 Detroit Ann Arbor
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News 03/04/11 Boston
Genzyme Rival Fails to Get FDA Approval 02/25/11 Boston
Genzyme Boss Henri Termeer Not Ready To Sell to Sanofi, Ride Into the Sunset, Sources Say 09/22/10 Boston
Xconomy Readers Set $20B Pricetag on Genzyme—Is That Too Rich for Sanofi-Aventis? 07/29/10 Boston
Genzyme in “Tough Spot” with Icahn Proxy Challenge—CEO Termeer Courting Key Shareholders 05/13/10 Boston
Cooking with the Genzyme Recipe: New Players Funding Rare Disease Drugs in Boston 04/12/10 Boston
Agreement Between Genzyme and San Diego Activist Shareholder Suggests Truce 01/07/10 San Diego
Shire Making Lemonade with Genzyme’s Lemons 12/15/09 Boston
Genzyme Resumes Shipments of Gaucher’s Drug from Allston Plant 12/01/09 Boston
Genzyme Competitor Lands Pfizer Deal 12/01/09 Boston
Genzyme’s Woes Piling Up as FDA Panel Says Data on Leukemia Drug are Lacking 09/01/09 Boston
Another Genzyme Rival Advancing 09/01/09 Boston
Genzyme Rival Gets FDA Nod 08/17/09 Boston
Shire’s Gaucher Drug Passes Key Trial, Putting More Heat on Genzyme During Shortage 08/03/09 Boston
Genzyme Rival, Actelion, Seeks to Fill Void Created by Cerezyme Shortage 07/09/09 Boston
Genzyme Offers Glimpse at Growth Engine, New Drugs for High Cholesterol, Gaucher’s 05/07/09 Boston
Conn. Agency Pumps $515K into Helix Therapeutics 03/05/09 Boston
Arzeda, Maker of Designer Enzymes, Prepares to Leave UW Roots with New Leader and VC Bucks 02/27/09 Seattle
Page 1 of 1